Genetic variant near cytosolic phospholipase A2 associated with schizophrenia

Craig J. Hudson; James L. Kennedy; Andrew Gotowiec; Anna Lin; Nicole King; Katherine Gojtan; Fabio Macciardi; Karl Skorecki; Herbert Y. Meltzer; Jerry J. Warsh; David F. Horrobin

doi:10.1016/0920-9964(96)00031-X

Genetic variant near cytosolic phospholipase A₂ associated with schizophrenia

Craig J. Hudson, James L. Kennedy^*, Andrew Gotowiec, Anna Lin, Nicole King, Katherine Gojtan, Fabio Macciardi, Karl Skorecki, Herbert Y. Meltzer, Jerry J. Warsh, David F. Horrobin

^*Corresponding author for this work

Psychiatry and Behavioral Sciences

Research output: Contribution to journal › Article › peer-review

75 Scopus citations

Abstract

Two studies were undertaken to determine a possible genetic basis for alterations in phospholipid metabolism in schizophrenia. Initial results demonstrated an association in 65 schizophrenics compared with a matched normal control population. A follow-up haplotype relative risk study of 44 triads (mother, father, affected offspring), confirmed the results seen in the association study. Results suggest that a genetic variant near the promotor region of the gene for cytosolic phospholipase A₂, the rate-limiting enzyme in the synthesis of prostaglandins from arachidonic acid, is associated with schizophrenia.

Original language	English (US)
Pages (from-to)	111-116
Number of pages	6
Journal	Schizophrenia Research
Volume	21
Issue number	2
DOIs	https://doi.org/10.1016/0920-9964(96)00031-X
State	Published - Aug 23 1996

Keywords

Genetic association
Genetic polymorphism
Haplotype relative risk
Phospholipase A
Schizophrenia

ASJC Scopus subject areas

Psychiatry and Mental health
Biological Psychiatry

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/0920-9964(96)00031-X

Cite this

@article{2986838011984cfe81f5b50fa2c7baf5,

title = "Genetic variant near cytosolic phospholipase A2 associated with schizophrenia",

abstract = "Two studies were undertaken to determine a possible genetic basis for alterations in phospholipid metabolism in schizophrenia. Initial results demonstrated an association in 65 schizophrenics compared with a matched normal control population. A follow-up haplotype relative risk study of 44 triads (mother, father, affected offspring), confirmed the results seen in the association study. Results suggest that a genetic variant near the promotor region of the gene for cytosolic phospholipase A2, the rate-limiting enzyme in the synthesis of prostaglandins from arachidonic acid, is associated with schizophrenia.",

keywords = "Genetic association, Genetic polymorphism, Haplotype relative risk, Phospholipase A, Schizophrenia",

author = "Hudson, {Craig J.} and Kennedy, {James L.} and Andrew Gotowiec and Anna Lin and Nicole King and Katherine Gojtan and Fabio Macciardi and Karl Skorecki and Meltzer, {Herbert Y.} and Warsh, {Jerry J.} and Horrobin, {David F.}",

note = "Funding Information: We thank Arturas Petronis, Mary Seeman, Astride Vicente, Patrick Massad and two anonymous reviewers for reviewing the manuscript. This study was supported by grants from the Medical Research Council of Canada, the Physician Services Incorporated Foundation, and Scotia Pharmaceuticals.",

year = "1996",

month = aug,

day = "23",

doi = "10.1016/0920-9964(96)00031-X",

language = "English (US)",

volume = "21",

pages = "111--116",

journal = "Schizophrenia Research",

issn = "0920-9964",

publisher = "Elsevier",

number = "2",

}

TY - JOUR

T1 - Genetic variant near cytosolic phospholipase A2 associated with schizophrenia

AU - Hudson, Craig J.

AU - Kennedy, James L.

AU - Gotowiec, Andrew

AU - Lin, Anna

AU - King, Nicole

AU - Gojtan, Katherine

AU - Macciardi, Fabio

AU - Skorecki, Karl

AU - Meltzer, Herbert Y.

AU - Warsh, Jerry J.

AU - Horrobin, David F.

N1 - Funding Information: We thank Arturas Petronis, Mary Seeman, Astride Vicente, Patrick Massad and two anonymous reviewers for reviewing the manuscript. This study was supported by grants from the Medical Research Council of Canada, the Physician Services Incorporated Foundation, and Scotia Pharmaceuticals.

PY - 1996/8/23

Y1 - 1996/8/23

N2 - Two studies were undertaken to determine a possible genetic basis for alterations in phospholipid metabolism in schizophrenia. Initial results demonstrated an association in 65 schizophrenics compared with a matched normal control population. A follow-up haplotype relative risk study of 44 triads (mother, father, affected offspring), confirmed the results seen in the association study. Results suggest that a genetic variant near the promotor region of the gene for cytosolic phospholipase A2, the rate-limiting enzyme in the synthesis of prostaglandins from arachidonic acid, is associated with schizophrenia.

AB - Two studies were undertaken to determine a possible genetic basis for alterations in phospholipid metabolism in schizophrenia. Initial results demonstrated an association in 65 schizophrenics compared with a matched normal control population. A follow-up haplotype relative risk study of 44 triads (mother, father, affected offspring), confirmed the results seen in the association study. Results suggest that a genetic variant near the promotor region of the gene for cytosolic phospholipase A2, the rate-limiting enzyme in the synthesis of prostaglandins from arachidonic acid, is associated with schizophrenia.

KW - Genetic association

KW - Genetic polymorphism

KW - Haplotype relative risk

KW - Phospholipase A

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=0030598906&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030598906&partnerID=8YFLogxK

U2 - 10.1016/0920-9964(96)00031-X

DO - 10.1016/0920-9964(96)00031-X

M3 - Article

C2 - 8873778

AN - SCOPUS:0030598906

VL - 21

SP - 111

EP - 116

JO - Schizophrenia Research

JF - Schizophrenia Research

SN - 0920-9964

IS - 2

ER -